(Q24245067)

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Cyclosporin for refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Cyclosporine treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Clinical evaluation and management of acute severe colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Surgery for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Review article: the management of severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Immunosuppressants and operation in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021

Inflammatory bowel disease: sorting out the treatment options.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004277.PUB2

7 January 2021